Purpose: Thyroid diseases and lipid metabolic abnormalities have been reported to be correlated. In patients with thyroid cancer, thyroid stimulating hormone levels are suppressed to prevent recurrence. Many studies have reported dyslipidemia associated with thyroid function, although its extent before and after thyroidectomy remains to be studied. This study aimed to determine the lipid levels for administering accurate lipid treatment in thyroid cancer patients post thyroidectomy. Methods: In total, 1,203 patients with thyroid cancer who underwent thyroidectomy between June 1, 2016 and December 31, 2016 at the Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University, were enrolled in the study. Of these, patients aged <19 years and taking medication for dyslipidemia were excluded. Finally, we enrolled 295 thyroid cancer patients who underwent thyroidectomy and whose lipid profiles were confirmed pre-and post-operatively. Results: The total cholesterol levels in the lobectomy group without levothyroxine supplementation were significantly increased 1 year after surgery than those before surgery (168.17±29.19 mg/dL vs. 182.50±34.03 mg/dL, P=0.003). Additionally, the triglyceride (TG) levels were significantly decreased in the lobectomy with levothyroxine supplementation and total thyroidectomy groups, whereas cholesterol and low-density lipoprotein-cholesterol (LDL-C) levels showed no significant change. No significant changes in the levels of cholesterol, LDL-C, and TG were observed in all the 3 groups. Conclusion: Extent of surgery and levothyroxine supplementation had an insignificant impact on the levels of cholesterol, LDL-C, TG, and high-density lipoprotein-cholesterol compared pre-and post-operatively.

Purpose We investigated the treatment response and prognosis using the neutrophil-to-lymphocyte ratio (NLR) and standardized uptake value (SUV) of 18 F-fluorodeoxyglucose positron emission tomography ( 18 F-FDG PET) in neoadjuvant settings. Methods Baseline NLR and maximum SUV (SUV max ) were retrospectively analyzed in 273 females with breast cancer who received neoadjuvant chemotherapy followed by surgery. Of these, 101 patients underwent 18 F-FDG PET after 3–4 neoadjuvant chemotherapy cycles, which allowed the measurement of ΔSUV max , an early reduction in SUV max . NLR and early SUV max reduction (ΔSUV max ) were classified as low and high, respectively, relative to the median values. Results The mean NLR was lower, and the mean ΔSUV max was higher in patients with pathologic complete response (pCR) than in those with residual tumors. The ΔSUV max was an independent variable associated with pCR. Furthermore, the high NLR group had poor recurrence-free survival (RFS) and overall survival. Among patients with ΔSUV max data, high NLR (adjusted hazard ratio, 2.82; 95% confidence intervals [CI], 1.26–6.28; P = 0.016) and low ΔSUV max (adjusted hazard ratio, 2.39; 95% CI, 1.07–5.34; P = 0.037) were independent prognostic factors for poor RFS. The categorization of the patients into four groups according to the combination of NLR and ΔSUV max showed that patients with high NLR and low ΔSUV max had significantly poorer RFS. Conclusion Baseline NLR and ΔSUV max were significantly associated with the prognosis of patients with breast cancer who received neoadjuvant chemotherapy. These results suggest that metabolic non-responders with defective immune systems have worse survival outcomes.